Latest NewsNov 4, 2024HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200604, a Best-in-Class BTLA Agonist Antibody for the Treatment of Inflammatory and Immunology Diseases All Filter By: Year2024202320222021202020192018201720162015Jun 23, 2023HiFiBiO Therapeutics Announces First Patient First Visit for the Evaluation of HFB200301 in Combination with Tislelizumab in Patients with DIS® Selected Advanced Solid TumorsBiotech2050 | Podcast | Jun 14, 2023HiFiBiO Therapeutics CEO Liang Schweizer Shares Her Professional Journey and the Company’s Pioneering DIS® Approach on the Biotech2050 PodcastApr 7, 2023HiFiBiO Therapeutics Announces Oral Presentation at 2023 American Association for Cancer Research (AACR) Annual MeetingMar 6, 2023Going Global: Insights on the Advantages of Biotech Globalization Published in Drug Discovery Today from HiFiBiO TherapeuticsJan 6, 2023HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200603< 1 2 3 4 5 6 … 17 >
